Rocket Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Rocket Pharmaceuticals, Inc. (RCKT) reported Net Income (Loss) Available to Common Stockholders, Basic of $123.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $123.21M.
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$47.59M.
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$42.54M.
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$50.33M.
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$223.12M.
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$258.75M.
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$245.59M.
- Rocket Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$221.86M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $123.21M 10-Q · filed 2026-08-10 | $75.62M 10-Q · filed 2026-08-10 | $33.08M derived: sum of 3 quarters · filed 2026-08-10 | -$17.25M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | -$47.59M 10-Q · filed 2026-05-07 | -$90.13M derived: sum of 2 quarters · filed 2026-05-07 | -$140.46M derived: sum of 3 quarters · filed 2026-05-07 | -$209.38M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | -$42.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$92.87M derived: sum of 2 quarters · filed 2026-02-26 | -$161.79M derived: sum of 3 quarters · filed 2026-08-10 | -$223.12M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$50.33M 10-Q · filed 2025-11-06 | -$119.25M derived: sum of 2 quarters · filed 2026-08-10 | -$180.59M 10-Q · filed 2025-11-06 | -$240.91M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | -$68.92M 10-Q · filed 2026-08-10 | -$130.25M 10-Q · filed 2026-08-10 | -$190.58M derived: sum of 3 quarters · filed 2026-08-10 | -$257.30M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | -$61.33M 10-Q · filed 2026-05-07 | -$121.66M derived: sum of 2 quarters · filed 2026-05-07 | -$188.38M derived: sum of 3 quarters · filed 2026-05-07 | -$258.03M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$60.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$127.05M derived: sum of 2 quarters · filed 2026-02-26 | -$196.69M derived: sum of 3 quarters · filed 2026-02-26 | -$258.75M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$66.72M 10-Q · filed 2025-11-06 | -$136.37M derived: sum of 2 quarters · filed 2025-11-06 | -$198.42M 10-Q · filed 2025-11-06 | -$258.08M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | -$69.65M 10-Q · filed 2025-08-07 | -$131.70M 10-Q · filed 2025-08-07 | -$191.36M derived: sum of 3 quarters · filed 2025-08-07 | -$253.26M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$62.05M 10-Q · filed 2025-05-08 | -$121.71M derived: sum of 2 quarters · filed 2025-05-08 | -$183.61M derived: sum of 3 quarters · filed 2025-05-08 | -$249.31M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$59.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$121.56M derived: sum of 2 quarters · filed 2025-02-27 | -$187.26M derived: sum of 3 quarters · filed 2025-02-27 | -$245.59M 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | -$61.90M 10-Q · filed 2024-11-07 | -$127.60M derived: sum of 2 quarters · filed 2024-11-07 | -$185.94M 10-Q · filed 2024-11-07 | -$252.66M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | -$65.70M 10-Q · filed 2024-08-06 | -$124.04M 10-Q · filed 2024-08-06 | -$190.76M derived: sum of 3 quarters · filed 2025-02-27 | -$248.51M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$58.34M 10-Q · filed 2024-05-07 | -$125.06M derived: sum of 2 quarters · filed 2025-02-27 | -$182.81M derived: sum of 3 quarters · filed 2025-02-27 | -$237.22M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$66.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$124.48M derived: sum of 2 quarters · filed 2025-02-27 | -$178.88M derived: sum of 3 quarters · filed 2025-02-27 | -$221.86M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$57.76M 10-Q · filed 2023-11-07 | -$112.16M derived: sum of 2 quarters · filed 2023-11-07 | -$155.14M 10-Q · filed 2023-11-07 | -$199.39M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | -$54.40M 10-Q · filed 2023-08-09 | -$97.38M 10-Q · filed 2023-08-09 | -$141.63M derived: sum of 3 quarters · filed 2024-02-27 | -$191.75M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | -$42.98M 10-Q · filed 2023-05-05 | -$87.23M derived: sum of 2 quarters · filed 2024-02-27 | -$137.35M derived: sum of 3 quarters · filed 2024-02-27 | -$171.87M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | -$44.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$94.36M derived: sum of 2 quarters · filed 2024-02-27 | -$128.89M derived: sum of 3 quarters · filed 2024-02-27 | -$169.07M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | -$50.12M 10-Q · filed 2022-11-04 | -$84.64M derived: sum of 2 quarters · filed 2022-11-04 | -$124.82M 10-Q · filed 2022-11-04 | -$185.74M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$34.52M 10-Q · filed 2022-08-09 | -$74.70M 10-Q · filed 2022-08-09 | -$135.62M derived: sum of 3 quarters · filed 2023-02-28 | -$164.70M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$40.18M 10-Q · filed 2022-05-06 | -$101.09M derived: sum of 2 quarters · filed 2023-02-28 | -$130.18M derived: sum of 3 quarters · filed 2023-02-28 | -$155.22M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$60.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$90.00M derived: sum of 2 quarters · filed 2023-02-28 | -$115.04M derived: sum of 3 quarters · filed 2023-02-28 | -$139.70M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | -$29.08M 10-Q · filed 2021-11-05 | -$54.12M derived: sum of 2 quarters · filed 2021-11-05 | -$78.78M 10-Q · filed 2021-11-05 | |||||
| 2020-06-30 | -$25.04M 10-Q · filed 2021-08-09 | -$49.70M 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | -$24.66M 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | -$77.27M 10-K · filed 2022-02-28 | |||||||
| 2018-12-31 | -$27.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$43.41M derived: sum of 2 quarters · filed 2021-03-01 | -$59.17M derived: sum of 3 quarters · filed 2021-03-01 | -$74.52M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | -$16.09M 10-Q · filed 2018-11-09 | -$31.86M derived: sum of 2 quarters · filed 2018-11-09 | -$47.20M 10-Q · filed 2018-11-09 | -$53.85M derived: sum of 4 quarters · filed 2019-03-08 | ||||
| 2018-06-30 | -$15.77M 10-Q · filed 2018-08-14 | -$31.11M 10-Q · filed 2018-08-14 | -$37.77M derived: sum of 3 quarters · filed 2019-03-08 | -$44.49M derived: sum of 4 quarters · filed 2019-03-08 | ||||
| 2018-03-31 | -$15.34M 10-Q · filed 2018-05-11 | -$22.00M derived: sum of 2 quarters · filed 2019-03-08 | -$28.72M derived: sum of 3 quarters · filed 2019-03-08 | -$32.05M derived: sum of 4 quarters · filed 2019-03-08 | ||||
| 2017-12-31 | -$6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$13.38M derived: sum of 2 quarters · filed 2019-03-08 | -$16.71M derived: sum of 3 quarters · filed 2019-03-08 | -$19.58M 10-K · filed 2019-03-08 | -$29.50M 10-K · filed 2018-03-07 | |||
| 2017-09-30 | -$6.72M 10-Q · filed 2018-11-09 | -$7.39M 10-Q · filed 2017-11-08 | -$10.05M derived: sum of 2 quarters · filed 2018-11-09 | -$12.92M 10-Q · filed 2018-11-09 | -$24.63M 10-Q · filed 2017-11-08 | $9.58M derived: sum of 4 quarters · filed 2019-03-08 | ||
| 2017-06-30 | -$3.33M 10-Q · filed 2018-08-14 | -$6.56M 10-Q · filed 2017-08-03 | -$6.20M 10-Q · filed 2018-08-14 | -$17.23M 10-Q · filed 2017-08-03 | $16.30M derived: sum of 3 quarters · filed 2019-03-08 | $5.17M derived: sum of 4 quarters · filed 2019-03-08 | ||
| 2017-03-31 | -$2.68M 10-Q · filed 2018-05-11 | -$10.67M 10-Q · filed 2017-05-10 | $19.63M derived: sum of 2 quarters · filed 2019-03-08 | $8.50M derived: sum of 3 quarters · filed 2019-03-08 | -$183.00K derived: sum of 4 quarters · filed 2019-03-08 | |||
| 2016-12-31 | $22.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $11.18M derived: sum of 2 quarters · filed 2019-03-08 | $2.50M derived: sum of 3 quarters · filed 2019-03-08 | -$7.57M 10-K · filed 2019-03-08 | -$42.85M 10-K · filed 2017-03-16 | |||
| 2016-09-30 | -$11.13M 10-Q · filed 2017-11-08 | -$19.81M derived: sum of 2 quarters · filed 2017-11-08 | -$29.88M 10-Q · filed 2017-11-08 | -$38.05M derived: sum of 4 quarters · filed 2017-11-08 | ||||
| 2016-06-30 | -$8.68M 10-Q · filed 2017-08-03 | -$18.75M 10-Q · filed 2017-08-03 | -$26.93M derived: sum of 3 quarters · filed 2017-08-03 | -$82.89M derived: sum of 4 quarters · filed 2017-08-03 | ||||
| 2016-03-31 | -$10.07M 10-Q · filed 2017-05-10 | -$18.24M derived: sum of 2 quarters · filed 2017-05-10 | -$74.20M derived: sum of 3 quarters · filed 2017-05-10 | -$76.59M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | -$8.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$64.13M derived: sum of 2 quarters · filed 2017-03-16 | -$66.52M derived: sum of 3 quarters · filed 2017-03-16 | -$68.11M 10-K · filed 2017-03-16 | ||||
| 2015-09-30 | -$55.96M 10-Q · filed 2016-11-09 | -$58.35M derived: sum of 2 quarters · filed 2016-11-09 | -$59.94M 10-Q · filed 2016-11-09 | -$63.23M derived: sum of 4 quarters · filed 2016-11-09 | ||||
| 2015-06-30 | -$2.39M 10-Q · filed 2016-08-10 | -$3.98M 10-Q · filed 2016-08-10 | -$7.27M derived: sum of 3 quarters · filed 2016-08-10 | -$10.75M derived: sum of 4 quarters · filed 2016-08-10 | ||||
| 2015-03-31 | -$1.59M 10-Q · filed 2016-05-11 | -$4.88M derived: sum of 2 quarters · filed 2016-05-11 | -$8.36M derived: sum of 3 quarters · filed 2016-05-11 | -$12.25M derived: sum of 4 quarters · filed 2016-05-11 | ||||
| 2014-12-31 | -$3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | -$6.77M derived: sum of 2 quarters · filed 2016-03-23 | -$10.65M derived: sum of 3 quarters · filed 2016-03-23 | -$13.80M 10-K · filed 2016-03-23 | ||||
| 2014-09-30 | -$3.48M 10-Q · filed 2015-11-12 | -$7.37M derived: sum of 2 quarters · filed 2015-11-12 | -$10.51M 10-Q · filed 2015-11-12 | |||||
| 2014-06-30 | -$3.88M 10-Q · filed 2015-08-07 | -$7.03M 10-Q · filed 2015-08-07 | ||||||
| 2014-03-31 | -$3.14M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |